Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ialuset Pro Derm
- Development stage
- Unknown
- Lead developer
- IBSA
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Ialuset Pro Derm is a topical healing cream formulated with a 0.4% concentration of hyaluronic acid (sodium salt), combining both high and low molecular weights. Developed by IBSA Pharma (formerly Laboratoires Genévrier), this medical device is designed to promote skin hydration and accelerate the healing of non-infected post-surgical wounds, burns, and other skin lesions. The high molecular weight hyaluronic acid remains on the skin surface to form a protective barrier, while the low molecular weight hyaluronic acid penetrates deeper into the tissues to stimulate cellular renewal and tissue regeneration. It is indicated for adults to support optimal re-epithelialization and improve the appearance of scars.
- Brand names
- Ialuset Pro Derm
02
Targets
CD44 (CD44 antigen)HMMR
Beyond the preview
Go deeper on Ialuset Pro Derm.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ialuset Pro Derm.